Loading...
XSTO
IMP A SDB
Market cap153mUSD
Apr 09, Last price  
27.20SEK
1D
-4.56%
1Q
-29.90%
IPO
-71.96%
Name

Implantica AG

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
96.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
139.50%
Revenues
1m
+67.22%
017,86728,000152,000387,000842,0001,408,000
Net income
-24m
L+14.02%
-3,125,157-4,554,122-4,805,000-10,277,000-15,361,000-20,824,000-23,744,000
CFO
-20m
L+24.75%
-1,757,217-3,727,144-3,573,000-10,364,000-11,472,000-15,958,000-19,908,000

Profile

Implantica AG, a medtech company, researches, develops, and sells medical implants for unmet medical needs in Switzerland. Its lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. The company also develops e-InVivo, a sensor implant to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, it develops UriControl, a remote controlled implant to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and MS patients to urinate on demand using the wireless platform. The company was founded in 2015 and is based in Vaduz, Liechtenstein. Implantica AG is a subsidiary of Implantica MediSwiss.
URL
IPO date
Sep 21, 2020
Employees
Domiciled in
LI
Incorporated in
LI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
1,408
67.22%
842
117.57%
Cost of revenue
24,508
20,516
Unusual Expense (Income)
NOPBT
(23,100)
(19,674)
NOPBT Margin
Operating Taxes
74
39
Tax Rate
NOPAT
(23,174)
(19,713)
Net income
(23,744)
14.02%
(20,824)
35.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
(59)
BB yield
0.00%
Debt
Debt current
314
Long-term debt
1,482
1,962
Deferred revenue
Other long-term liabilities
575
267
Net debt
(86,126)
(106,989)
Cash flow
Cash from operating activities
(19,908)
(15,958)
CAPEX
(87)
(61)
Cash from investing activities
(3,154)
41,086
Cash from financing activities
(431)
(937)
FCF
(22,950)
(20,760)
Balance
Cash
87,922
108,951
Long term investments
Excess cash
87,852
108,909
Stockholders' equity
125,048
144,087
Invested Capital
38,667
36,262
ROIC
ROCE
EV
Common stock shares outstanding
283,091
283,112
Price
23.90
-39.87%
39.75
-38.85%
Market cap
6,765,865
-39.88%
11,253,684
-38.51%
EV
6,677,514
11,145,228
EBITDA
(21,476)
(19,222)
EV/EBITDA
Interest
Interest/NOPBT